Fast-growing growth hormone transgenic coho salmon (Oncorhynchus kisutch) show a lower incidence of vaterite deposition and malformations in sagittal otoliths.
Otolith
Salmon
Transgenic
Vaterite
Journal
The Journal of experimental biology
ISSN: 1477-9145
Titre abrégé: J Exp Biol
Pays: England
ID NLM: 0243705
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
received:
08
02
2022
accepted:
17
08
2022
pubmed:
25
8
2022
medline:
12
10
2022
entrez:
24
8
2022
Statut:
ppublish
Résumé
In fish otoliths, CaCO3 normally precipitates as aragonite, and more rarely as vaterite or calcite. A higher incidence of vaterite deposition in otoliths from aquaculture-reared fish has been reported and it is thought that high growth rates under farming conditions might promote its deposition. To test this hypothesis, otoliths from growth hormone (GH) transgenic coho salmon and non-transgenic fish of matching size were compared. Once morphometric parameters were normalized by animal length, we found that transgenic fish otoliths were smaller (-24%, -19%, -20% and -30% for length, width, perimeter and area, respectively; P<0.001) and rounder (-12%, +13.5%, +15% and -15.5% in circularity, form factor, roundness and ellipticity; P<0.001) than otoliths from non-transgenic fish of matching size. Interestingly, transgenic fish had smaller eyes (-30% eye diameter) and showed a strong correlation between eye and otolith size. We also found that the percentage of otoliths showing vaterite deposition was significantly smaller in transgenic fish (21-28%) than in non-transgenic fish (69%; P<0.001). Likewise, the area affected by vaterite deposition within individual otoliths was reduced in transgenic fish (21-26%) compared with non-transgenic fish (42.5%; P<0.001). Our results suggest that high growth rates per se are not sufficient to cause vaterite deposition in all cases, and that GH overexpression might have a protective role against vaterite deposition, a hypothesis that needs further investigation.
Identifiants
pubmed: 36000289
pii: 277172
doi: 10.1242/jeb.244099
pmc: PMC9659332
pii:
doi:
Substances chimiques
Growth Hormone
9002-72-6
Calcium Carbonate
H0G9379FGK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Canadian Regulatory System for Biotechnology
ID : 61740
Organisme : Ministerio de Ciencia e Innovacion
ID : RTI2018-100757-B-100
Organisme : Serra Húnter
Organisme : Ministerio de Ciencia y Tecnología
ID : RTI2018-100757-B-100
Organisme : University of Barcelona: Universitat de Barcelona
Informations de copyright
© 2022. Published by The Company of Biologists Ltd.
Déclaration de conflit d'intérêts
Competing interests The authors declare no competing or financial interests.
Références
PLoS One. 2018 Sep 5;13(9):e0203537
pubmed: 30183762
Front Endocrinol (Lausanne). 2011 Sep 20;2:30
pubmed: 22649371
J Exp Biol. 2017 Aug 15;220(Pt 16):2965-2969
pubmed: 28596212
Behav Ecol Sociobiol. 2017;71(12):179
pubmed: 29213179
Am J Physiol Regul Integr Comp Physiol. 2011 Jul;301(1):R236-43
pubmed: 21490369
FEBS J. 2019 Jan;286(1):66-81
pubmed: 30521091
J Fish Biol. 2017 Feb;90(2):549-558
pubmed: 27461067
FEBS J. 2008 May;275(10):2512-23
pubmed: 18410381
Horm Metab Res. 1992 Jan;24(1):10-4
pubmed: 1612552
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Brain Behav Evol. 1994;44(3):149-55
pubmed: 7987663
Ecol Evol. 2020 Nov 22;11(1):365-375
pubmed: 33437435
PLoS One. 2011;6(11):e27055
pubmed: 22110601
Dev Biol. 2004 Dec 15;276(2):391-402
pubmed: 15581873
J Proteomics. 2019 Feb 10;192:114-124
pubmed: 30153513
Mech Dev. 2005 Jun;122(6):791-803
pubmed: 15905077
J Comp Physiol B. 2012 Oct;182(7):921-34
pubmed: 22581071
Gen Comp Endocrinol. 1995 Jan;97(1):13-30
pubmed: 7713377
PLoS One. 2015 Mar 24;10(3):e0121102
pubmed: 25803855
Gen Comp Endocrinol. 2013 Oct 1;192:136-48
pubmed: 23791761
J Fish Biol. 2012 Oct;81(5):1715-29
pubmed: 23020570
Sci Rep. 2018 May 30;8(1):8384
pubmed: 29849112
PeerJ. 2014 Sep 23;2:e586
pubmed: 25279266
Front Endocrinol (Lausanne). 2020 Nov 06;11:596585
pubmed: 33240222
Gen Comp Endocrinol. 2008 Oct;159(1):26-37
pubmed: 18713628
J Exp Biol. 2020 Jun 25;223(Pt 12):
pubmed: 32414874
Int J Mol Sci. 2021 Dec 03;22(23):
pubmed: 34884912
FASEB J. 2019 Jun;33(6):6877-6886
pubmed: 30840836
Sci Rep. 2016 Apr 28;6:25249
pubmed: 27121086
Gen Comp Endocrinol. 2010 Nov 1;169(2):130-7
pubmed: 20736011